Updates are available Correction dated 2023-03-06

Article History

Received: 29 April 2021

Accepted: 3 August 2021

First Online: 21 August 2021

Change Date: 6 March 2023

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1186/s10194-023-01549-6

Declarations

:

: All participants gave their written consent after receiving detailed oral and written information and the study was conducted in accordance with the Helsinki II Declaration of 1964, with later revisions. The Ethical Committee of Copenhagen (H-3-2012-073) approved the study. All participants signed a written informed consent after a thorough explanation of study procedures. The study was registered at ExternalRef removed (NCT02202486). Other sub-studies under the same umbrella protocol have been published elsewhere [CitationRef removed, CitationRef removed].

: Not applicable.

: FMA has received lecturing fee and/or served as advisory board member for Teva, Lundbeck, Eli Lilly and Novartis. FMA is principal investigator for phase 4 trials for Novartis and Teva.RDI reported no conflicts of interests.MAK reports no conflicts of interests.JMR reports no conflicts of interests.FW reports no conflicts of interests.HBWL reports no conflicts of interests.MA reports receiving consulting fees and advisory boards fees from Alder, Allergan, Amgen, Eli Lilly, Lundbeck, Novartis, and Teva, fees for serving as a principal investigator, paid to his institution, from Alder, Allergan, Amgen, Electro-Core, Eli Lilly, Lundbeck, Novartis, and Teva, and grant support, paid to his institution, from Novo Nordisk Foundation, Novartis, and Lundbeck Foundation.